Drugs / 68Ga-RM2
68Ga-RM2
also known as
BAY 86-7548 · 68-Ga-DOTA-Bombesin Analog BAY86-7548 · 68Ga-Bombesin Antagonist BAY86-7548 · [68-Ga]-labeled Bombesin Analog BAY86-7548 · Ga-68-labeled Bombesin Antagonist BAY 86-7548 · [68Ga]Ga-RM2 · Bombesin (68Ga) labeled · Gallium Ga68-labeled GRPR antagonist RM2 · +1 more
Diagnostic / imaging agent targets GRPR via inhibition
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01205321 | Nov 2010 → Nov 2011 | — | Lantheus Biosciences Ltd. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03949517 | Apr 2019 → Mar 2022 | prostate cancer | Andrei Iagaru | Completed | No outcome recorded |
| Phase 1/2 | NCT03831711 | Mar 2019 → Nov 2021 | estrogen-receptor positive breast cancer | Andrei Iagaru | Completed | No outcome recorded |
| Phase 1/2 | NCT02483884 | May 2015 → Dec 2016 | prostate cancer | Lantheus Biosciences Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 27 trials | ||||||
| Phase 2 | NCT06484361 | Sep 2020 → Sep 2025 | prostate cancer | IRCCS San Raffaele | Unknown | No outcome recorded |
| Phase 2 | NCT05806853 | Jun 2020 → Oct 2022 | prostate cancer | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 2 | NCT04264208 | Feb 2020 → Nov 2022 | prostate cancer | Andrei Iagaru | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03606837 | Jul 2019 → Jun 2023 | prostate cancer | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 2 | NCT03809078 | Jan 2019 → Mar 2022 | prostate cancer | Andrei Iagaru | Completed | No outcome recorded |
| Phase 2 | NCT03604757 | Apr 2018 → Dec 2019 | prostate cancer | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 2 | NCT03113617 | Apr 2017 → Dec 2021 | prostate adenocarcinoma | Andrei Iagaru | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT02624518 | Nov 2015 → Jul 2021 | prostate adenocarcinoma | Andrei Iagaru | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03731026 | Nov 2018 → Nov 2023 | breast cancer | Lightpoint Medical Limited | Unknown | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-RM2 | “gallium Ga 68-labeled gastrin-releasing peptide receptor (GRPR) antagonist BAY86-7548 (68Ga-RM2) positron emission tomography (PET)/computed tomography (CT) works in detecting...” NCT03113617 ↗ |
| Known as | 68-Ga-DOTA-Bombesin Analog BAY86-7548 | “68-Ga-DOTA-Bombesin Analog BAY86-7548” NCT03831711 ↗1“68Ga-DOTA-Bombesin Analog BAY86-7548” NCT03113617 ↗ |
| Known as | 68Ga-Bombesin Antagonist BAY86-7548 | “68-Ga-Bombesin Antagonist BAY86-7548” NCT03831711 ↗1“68Ga-Bombesin Antagonist BAY86-7548” NCT03113617 ↗ |
| Known as | [68-Ga]-labeled Bombesin Analog BAY86-7548 | “[68-Ga]-labeled Bombesin Analog BAY86-7548” NCT03831711 ↗1“[68Ga]-labeled Bombesin Analog BAY86-7548” NCT03113617 ↗ |
| Known as | [68Ga]Ga-RM2 | “[68Ga]Ga-RM2 (a radiolabeled GRPR antagonist)” PMID 41656418 ↗ Feb 2026 |
| Known as | BAY 86-7548 | “68Ga-RM2 (BAY86-7548) is also identified as a synthetic bombesin receptor antagonist.” NCT02624518 ↗ |
| Known as | Bombesin (68Ga) labeled | “Bombesin (68Ga) labeled (BAY86-7548)” NCT01205321 ↗ |
| Known as | Ga-68-labeled Bombesin Antagonist BAY 86-7548 | “Ga-68-labeled Bombesin Antagonist BAY 86-7548” NCT03831711 ↗1“Ga-68-labeled Bombesin Antagonist BAY 86-7548” NCT03113617 ↗ |
| Known as | Gallium Ga68-labeled GRPR antagonist RM2 | “Gallium Ga68-labeled GRPR antagonist RM2” NCT02483884 ↗ |
| Known as | RM-2 GA-68 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4301788 ↗ |
| Action | Inhibit | “Gallium Ga68-labeled GRPR antagonist RM2” NCT02483884 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga Labeled PET Tracer BAY86-7548” NCT01205321 ↗ |
| Route | Intravenous | “single intravenous bolus injection of 140 MBq BAY86-7548” NCT01205321 ↗ |
| Target | GRPR | “GRPR antagonist” NCT03113617 ↗ |